UroStream

We are excited to share the upcoming Pujiang Genitourinary Oncology Academic Conference 2025 Webinar taking place on August 27, 2025. 14:00–15:30 (Dublin/London) | 15:00–16:30 CET | 21:00–22:30 CST This online…

On July 10–11, 2025, Professor Steven Campbell, Chair of Urology at West Virginia University, visited the Sun Yat-sen University Cancer Center (SYSUCC) for a two-day academic exchange. His visit brought an international, cutting-edge perspective to SYSUCC’s Department of Urology while also showcasing the department’s achievements to peers worldwide.

From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.

Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.

A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.

The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, in collaboration with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Centered around the theme “Global Wisdom, Chinese Practice, Precision Breakthroughs,” the event brought together leading experts to discuss cutting-edge progress and clinical insights in prostate cancer care. In an exclusive interview with Oncology Frontier – Urology Frontier, Professor Xiaojian Qin of Fudan University Shanghai Cancer Center shared his views on how the guiding philosophy in prostate cancer treatment is evolving.

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, alongside the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer…

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress, held from June 27–28 in Shanghai, was organized in conjunction with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC),…

On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.

As the tides of the Pujiang River surge forward, so too does China's momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai from June 27–28. The event gathered leading experts from China and abroad to exchange the latest advances and clinical practices in prostate cancer. In an exclusive interview with Oncology Frontier – Urology Frontier, Congress Chair and Professor Dingwei Ye of Fudan University Shanghai Cancer Center shared his perspectives on the current status and future of prostate cancer care in China, along with recent innovations in surgical treatment.